Nick Carter

Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study

Alejandro Llanos‐Cuentas, Marcus Lacerda, Ronnatrai Rueangweerayut et al. · The Lancet · 2013 · 242 citations

Antiparasitic Agent, Medicine, Malaria +6

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase–deficient children receiving dapsone

Allan Pamba, Naomi D. Richardson, Nick Carter et al. · Blood · 2012 · 128 citations

Impact of Therapeutic Immunization on HIV‐1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection

Sabine Kinloch‐de Loes, Bruno Hoen, Don Smith et al. · The Journal of Infectious Diseases · 2005 · 114 citations

Immunology, Immunodominance, Antiviral Drug +17

Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the Phase 2b DETECTIVE trial

Pamela L. St. Jean, Zhengyu Xue, Nick Carter et al. · Malaria Journal · 2016 · 99 citations · Full text

Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials

Nick Carter, Allan Pamba, Stephan Duparc et al. · Malaria Journal · 2011 · 81 citations · Full text